Health · 5 views
Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer
Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.
AI Summary
The PEACE‑1 phase 3 trial, followed for almost eight years, showed that adding abiraterone to standard androgen deprivation therapy (ADT) gives a lasting survival benefit for men diagnosed with de‑novo metastatic castration‑sensitive prostate cancer (mCSPC). The study compared two doublet regimens: ADT plus docetaxel chemotherapy and ADT plus abiraterone. Results from the ESMO 2026 presentation found no significant difference in overall survival between the two combinations, supporting early treatment intensification with either option.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Five ways to look after yourself as winter approachesContinue reading
- NHS consultants to go on two-day strike in England in November, says BMAContinue reading
- Novel Drug Doubles PFS in Heavily Pretreated, HR-Positive Breast CancerContinue reading
- A virus that afflicts cows makes the jump to a humanContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow